Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Bolsa de Madrid  >  Pharma Mar, S.A.    PHM   ES0169501030

PHARMA MAR, S.A.

(PHM)
  Report
SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

PharmaMar signs an agreement with Valeo Pharma to commercialize Yondelis in Canada

share with twitter share with LinkedIn share with facebook
share via e-mail
01/22/2020 | 10:08am EDT

Madrid - PharmaMar (MSE: PHM) has announced today a licensing agreement with Valeo Pharma, Inc. (CSE: VPH) to commercialize the marine-derived anticancer drug Yondelis (trabectedin) in Canada.

Under the terms of the agreement, PharmaMar will receive a non-disclosed upfront payment and will be eligible for additional remunerations, including regulatory milestone payments. PharmaMar will retain the exclusive production rights of the product and will sell the product to Valeo Pharma for its clinical and commercial use.

This new agreement follows PharmaMar's announcement on August 26th , in regard to the agreement entered with Janssen Products LP (Janssen), by which PharmaMar recovered the commercialization rights of the product in more than 40 countries formerly licensed to Janssen, where trabectedin has already been approved.

Trabectedin is currently provided to patients in Canada for the treatment of Soft Tissue Sarcoma and Relapsed Ovarian Cancer. Former product licensee Janssen will continue to commercialize the product in Canada until its marketing authorizations are formally transferred to Valeo Pharma.

'We are excited at the opportunity of taking over the commercialization of Yondelis in Canada. Yondelis is a recognized global standard of care in the treatment of soft tissue sarcoma. We look forward to using our resources and expertise to expand the market for this differentiated drug to its full potential', said Steve Saviuk, Valeo Pharma's President and CEO. 'Yondelis is a good example of the type of innovative drugs we're looking to add to our expanding product portfolio. Considering the product is already on the Canadian market, we expect Yondelis to contribute to our growing revenues in the coming quarters'.

Commenting on the licensing of Yondelis to Valeo, Jose Maria Fernandez, President of PharmaMar stated: 'We are pleased to have partnered Yondelis with Valeo for the Canadian market. We see Valeo's infrastructure and internal capabilities playing a key role in helping us maximize access to this unique drug for as many Canadian sarcoma and ovarian cancer patients as possible and look forward to a long and mutually beneficial partnership with Valeo'.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi).

About Valeo Pharma, Inc.

Valeo Pharma is a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada. With a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products, Valeo Pharma has a growing portfolio of innovative products and the full infrastructure to properly manage these products through all stages of commercialization. Headquartered in Kirkland, Quebec, Valeo Pharma has all capabilities internally to register and market health care solutions for Canadian patients.

About Yondelis

Yondelis (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, a type of sea squirt. Yondelis exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.

Contact:

Alfonso Ortin

Tel: +34 609493127

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
PHARMA MAR, S.A. -0.99% 4.61 End-of-day quote.-1.91%
VALEO 6.62% 16.02 Real-time Quote.-52.16%
VALEO PHARMA INC. 11.11% 0.3 Delayed Quote.-33.33%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PHARMA MAR, S.A.
04/06PHARMA MAR S A : Liquidity and counterparty agreements
PU
03/13PHARMA MAR S A : says test of potential coronavirus drug promising
RE
03/06PHARMA MAR S A : PharmaMar shares jump after coronavirus diagnosis kit gets EU c..
RE
02/20PHARMA MAR S A : PharmaMar - Lurbinectedin receives Orphan Drug designation from..
AQ
01/22PharmaMar signs an agreement with Valeo Pharma to commercialize Yondelis in C..
AQ
2019PHARMA MAR S A : PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agree..
AQ
2019PHARMA MAR : PharmaMar enters into a new licensing agreement with Janssen for Yo..
AQ
2019PHARMA MAR : PharmaMar and Luye Pharma sign License agreement for Development an..
AQ
2019PHARMA MAR : Calificaciones crediticias
PU
2019PHARMA MAR : PharmaMar announces its new immunotherapy research program
PU
More news
Financials (EUR)
Sales 2020 257 M
EBIT 2020 210 M
Net income 2020 192 M
Finance 2020 97,0 M
Yield 2020 -
P/E ratio 2020 5,33x
P/E ratio 2021 23,6x
EV / Sales2020 3,60x
EV / Sales2021 4,59x
Capitalization 1 023 M
Chart PHARMA MAR, S.A.
Duration : Period :
Pharma Mar, S.A. Technical Analysis Chart | PHM | ES0169501030 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 5,17  €
Last Close Price 4,61  €
Spread / Highest target 30,2%
Spread / Average Target 12,1%
Spread / Lowest Target -4,56%
EPS Revisions
Managers
NameTitle
José Maria Fernández de Sousa-Faro Executive Chairman, President & CEO
Pascal M. Besman Chief Operating Officer
Maria Luisa de Francia Caballero Chief Financial Officer
Nadia Badri Vice President-Medical Affairs
Carmen Cuevas Marchante Director-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
PHARMA MAR, S.A.-1.91%1 062
CSL LIMITED-3.46%82 637
BIOGEN INC.4.94%55 070
SAMSUNG BIOLOGICS CO.,LTD.0.86%26 232
ALEXION PHARMACEUTICALS-16.99%19 942
GRIFOLS-2.17%19 665